Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Gains from Investment Securities (2016 - 2022)

Wave Life Sciences (WVE) has disclosed Gains from Investment Securities for 5 consecutive years, with $2.6 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Gains from Investment Securities rose 4842.59% year-over-year to $2.6 million, compared with a TTM value of $4.9 million through Dec 2022, changed N/A, and an annual FY2022 reading of $12.0 million, up 166.92% over the prior year.
  • Gains from Investment Securities was $2.6 million for Q3 2019 at Wave Life Sciences, up from $2.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.6 million in Q1 2019 and bottomed at -$212000.0 in Q4 2017.
  • Average Gains from Investment Securities over 5 years is $816829.9, with a median of $186428.0 recorded in 2015.
  • The sharpest move saw Gains from Investment Securities crashed 142.32% in 2017, then skyrocketed 233200.0% in 2019.
  • Year by year, Gains from Investment Securities stood at $2.2 million in 2015, then crashed by 77.38% to $501000.0 in 2016, then plummeted by 142.32% to -$212000.0 in 2017, then skyrocketed by 74.53% to -$54000.0 in 2018, then surged by 4842.59% to $2.6 million in 2019.
  • Business Quant data shows Gains from Investment Securities for WVE at $2.6 million in Q3 2019, $2.3 million in Q2 2019, and $2.6 million in Q1 2019.